It is a blood-thinner or oral anti-coagulant that is manufactured by Bayer HealthCare, the.
J&J and Bayer's Xarel to cuts recurrence of dangerousPatients needing blood thinners are usually on several other drugs and once daily dosing can improve compliance.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.Xarelto, otherwise known as rivaroxaban, is a prescribed blood thinner manufactured by Bayer and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson.Eliquis and Pradaxa are both better than warfarin in preventing stroke.Biotech Values Message Board: Bayer, JNJ Report Phase-2 Xarelto Data in ACS.Medical education courses for cardiologists and general practitioners are also organized.Bayer is seeking FDA approval of Xarelto for the indication on the basis of.
Physicians prefer the breadth of its data from clinical trials.
After a slow launch, prescription trends are improving and the third quarter showed consistent weekly growth.Pharmaceutical sales grew by 11 percent in the quarter, driven mainly by sales of the brands Invega, Sustenna, Remicade, Simponi, Stelara, Velcade and Prezista and new products like Xarelto, Invokana, and Zytiga.
I wrote this article myself, and it expresses my own opinions.
Bayer AG Johnson Johnsons Xarelto Gets FDA Priority ReviewThe race is heating up and the participants have different strengths and weaknesses.
Xarelto Could Be Another Blockbuster (JNJ, $66.64
Xarelto Lawsuits - About Xarelto Bleeding CasesThe Institute for Safe Medication Practices (ISMP) in its October 2013 report placed anticoagulant drugs at the top of the list of serious adverse events reported to the FDA, with Pradaxa leading the pack.
A study of 3,396 patients showed that the oral blood thinner Xarelto cut the risk of recurring, life-threatening blood clots.
EU Backs Bayer/JNJ's Xarelto - Analyst BlogBut convenience is not necessarily a deciding factor in choosing a drug.
Bayer, J&J Anti-Stroke Drug Xarelto Gets Final Nod From
Xarelto National Litigation: Recent Update | Searcy Law
Pharmalot, Pharmalittle: J&J and Bayer win their first
J&J, Bayer get FDA-response letter on Xarelto - MarketWatch
A Study of Rivaroxaban (JNJ-39039039) on the VenousBroad label: Xarelto has a broad label, the widest of all three, with seven approved indications.Eliquis has been launched in 13 countries in Europe, four more to follow soon.Among the three leading new anticoagulants, Xarelto and Pradaxa are charging ahead in sales, while Eliquis is merely crawling.Pradaxa was the first approved among the newer anticoagulants, introduced in the U.S. in 2010. The company is privately owned, therefore sales forecasts are not available.
J&J, Bayer Cleared of Responsibility at Xarelto TrialEurope is an important market because the drug is used mainly in hospitals and so it favors the marketing strategy.Longer-term use of the oral blood thinner Xarelto significantly cut the risk of recurrence of potentially life-threatening blood clots with no additional major.
Someone in the U.S. has filed a lawsuit over its safety concerns.Hospital presence is a promising avenue but to build it up is time-consuming: it requires expensive stocking of the drug, educational courses for doctors and major advertising campaigns.